Allarity Therapeutics, Inc. Common Stock
ALLRStock
$1.17+10.48%52W
Market Cap$18.62M
P/E—
Div yield—
Beta0.56
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.17%
Price vs S&P 500 (4W)-21.22%
VGM Score52.44
Market Capitalization$18.62M
Earnings Surprise History
Q1 26-0.17est. -0.22
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALLRAllarity Therapeutics, Inc. Common Stock | — | — | C | $1.17 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Allarity Therapeutics is a clinical-stage pharmaceutical company developing stenoparib, an oral small-molecule inhibitor for advanced recurrent ovarian cancer. The company uses its proprietary Drug Response Predictor (DRP) technology to identify patients most likely to benefit from treatment, combining precision medicine with oncology. Operating in Denmark and the United States, Allarity is focused on addressing a significant unmet medical need in ovarian cancer treatment.